Clinical Trials

DermatologicGenitourinaryThoracic

24 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT05065736 2026-03-19

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Phase EARLY_PHASE1 Recruiting

4 enrolled

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Neoplasms

NCT06128343 2026-03-19

BACAP-2

1,500 enrolled

Adenocarcinoma, Carcinoma, Neoplasms

NCT06505122 2026-03-19

DLR RCT

60 enrolled

Phase 2 Not yet recruiting

Neoplasms

NCT06677593 2026-03-19

DEEP 2

Active not recruiting

37 enrolled

Neoplasms, Pain, Pulmonary Disease, Chronic Obstructive

NCT07149207 2026-03-19

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

30 enrolled

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT07191730 2026-03-19

ML-CardioTox

600 enrolled

Breast

Breast Neoplasms, Heart Failure, Neoplasms, Cardiotoxicity

NCT07398677 2026-03-19

SchoolCare

128 enrolled

Phase NA Not yet recruiting

Neoplasms

NCT07481890 2026-03-19

Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.

46 enrolled

Phase 2/3 Active not recruiting

Neoplasms

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02501174 2026-03-18

CONSOG

2,914 enrolled

Neoplasms

NCT06298357 2026-03-18

Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation

Phase 1 Completed

11 enrolled

Neoplasms

NCT06658405 2026-03-18

HPV2

Phase 2 Recruiting

85 enrolled

Neoplasms

NCT06787014 2026-03-18

ENETSSurgSmInt

3,200 enrolled

Intestinal Obstruction, Neoplasm Metastasis, Neoplasms

NCT07202507 2026-03-18

SNOOZE

20 enrolled

Neoplasms

NCT07479199 2026-03-18

Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors

70 enrolled

Thoracic

Neoplasms, Pain, Thoracic Neoplasms

NCT07201038 2026-03-17

UF-WGS

50 enrolled

Phase 2/3 Not yet recruiting

Neoplasms

NCT07476443 2026-03-17

VitC-CoQ10

75 enrolled

Neoplasms

NCT07476495 2026-03-17

LUCID

100 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT07478536 2026-03-17

CHAS3

350 enrolled

Neoplasms, Prostatic Neoplasms

NCT00420563 2026-03-16

PAL-ANGI

Phase 2 Completed

88 enrolled

Neoplasms

NCT01198119 2026-03-16

NBI-CAB

Phase 2 Terminated

23 enrolled

Mouth Neoplasms, Neoplasms

NCT01248429 2026-03-16

TKI-CPK

154 enrolled

Neoplasms, Myalgia

NCT01374620 2026-03-16

PAL-ANGI2

Phase 1 Completed

28 enrolled

Neoplasms

NCT01415258 2026-03-16

VULNERABILITE

209 enrolled

Neoplasms

NCT01721343 2026-03-16

Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer

516 enrolled

Neoplasms, Pain

NCT02121730 2026-03-16

FRISC

2,500 enrolled

Kidney Neoplasms, Neoplasms

NCT02439047 2026-03-16

MESO-PATCH

Phase NA Terminated

6 enrolled

Neoplasms

NCT05371756 2026-03-16

TIOB

10,000 enrolled

Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

64 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05887882 2026-03-16

PNOC028

Phase 1 Recruiting

24 enrolled

Neoplasms

NCT06072833 2026-03-16

Characterizing and Addressing Financial Toxicity in AYAs With Cancer

26 enrolled 8 charts

Neoplasms

NCT06730204 2026-03-16

Standardized Nutritional Management of Pediatric Patients With Solid Tumors

400 enrolled

Neoplasms

NCT07472686 2026-03-16

iCARE4Lynch

400 enrolled

Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Neoplasms

NCT07473518 2026-03-16

Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy

2,550 enrolled

Neoplasms, Thyroid Neoplasms

NCT07474025 2026-03-16

Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses

Phase 1 Active not recruiting

30 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT07474168 2026-03-16

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

9 enrolled

Neoplasms

NCT00580515 2026-03-13

Trial of Family Focused Grief Therapy in Palliative Care and Bereavement

700 enrolled

DermatologicGastrointestinalSarcoma

Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT01247779 2026-03-13

ROBO-GYN

386 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT01596816 2026-03-13

CKNO-PRO

Phase 2 Completed

76 enrolled

GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms

NCT01641484 2026-03-13

ANOXICOL

Phase NA Terminated

9 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasms

NCT03652298 2026-03-13

NeuroPrevPTSD

Phase 2 Terminated

19 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Prostatic Neoplasms, Stress Disorders, Post-Traumatic, Colorectal Neoplasms

NCT07328321 2026-03-13

CPAQ-8-BC

Phase 1 Not yet recruiting

101 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT07454031 2026-03-13

Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

22 enrolled

Neoplasm Metastasis, Neoplasms

NCT07469683 2026-03-13

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

Carcinoma, Renal Cell, Neoplasms

NCT07469761 2026-03-13

MISTRAL

120 enrolled

Frailty, Neoplasms

NCT07471009 2026-03-13

SPAR

120 enrolled